Last edition
News about "anti-IL-15 antibody"
Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease
Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.
Anti-IL-15 Antibody | 03/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members